$AVDL
AVADEL PHARMACEUTICALS PLC

2021 Q1 Form 10-Q Financial Statement

#000101247721000008 Filed on May 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $12.24M
YoY Change -100.0% -25.52%
Cost Of Revenue $0.00 $2.457M
YoY Change -100.0% -24.77%
Gross Profit $0.00 $9.786M
YoY Change -100.0% -25.7%
Gross Profit Margin 79.93%
Selling, General & Admin $11.01M $7.913M
YoY Change 39.16% -24.25%
% of Gross Profit 80.86%
Research & Development $3.852M $5.530M
YoY Change -30.34% -24.55%
% of Gross Profit 56.51%
Depreciation & Amortization $220.0K $460.0K
YoY Change -52.17% 24.32%
% of Gross Profit 4.7%
Operating Expenses $14.86M $13.44M
YoY Change 10.57% -24.37%
Operating Profit -$14.81M -$6.497M
YoY Change 127.97% -20.45%
Interest Expense -$1.930M -$3.190M
YoY Change -39.5% 4.25%
% of Operating Profit
Other Income/Expense, Net $0.00 -$310.0K
YoY Change -100.0% 0.98%
Pretax Income -$16.05M -$10.38M
YoY Change 54.72% -22.53%
Income Tax -$2.607M -$9.510M
% Of Pretax Income
Net Earnings -$13.45M -$865.0K
YoY Change 1454.34% -93.36%
Net Earnings / Revenue -7.07%
Basic Earnings Per Share -$0.23 -$0.02
Diluted Earnings Per Share -$0.23 -$0.02
COMMON SHARES
Basic Shares Outstanding 58.44M shares 41.06M shares
Diluted Shares Outstanding 58.44M shares 41.06M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $206.5M $113.5M
YoY Change 81.94% 42.05%
Cash & Equivalents $59.17M $73.51M
Short-Term Investments $147.3M $40.00M
Other Short-Term Assets $149.0K $155.0K
YoY Change -3.87% -85.1%
Inventory $3.523M
Prepaid Expenses $4.990M $1.933M
Receivables $8.500M $8.797M
Other Receivables $22.20M $2.600M
Total Short-Term Assets $242.3M $131.0M
YoY Change 85.01% 27.86%
LONG-TERM ASSETS
Property, Plant & Equipment $344.0K $472.0K
YoY Change -27.12% -73.01%
Goodwill $16.84M $18.49M
YoY Change -8.95% 0.0%
Intangibles $610.0K
YoY Change -57.28%
Long-Term Investments $1.500M
YoY Change 0.0%
Other Assets $27.72M $47.52M
YoY Change -41.68% 31.56%
Total Long-Term Assets $50.63M $76.75M
YoY Change -34.04% 7.82%
TOTAL ASSETS
Total Short-Term Assets $242.3M $131.0M
Total Long-Term Assets $50.63M $76.75M
Total Assets $292.9M $207.7M
YoY Change 41.02% 19.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.824M $6.790M
YoY Change -58.41% 63.61%
Accrued Expenses $4.297M $14.86M
YoY Change -71.08% 1.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $9.120M $32.34M
YoY Change -71.8% 3.12%
LONG-TERM LIABILITIES
Long-Term Debt $141.5M $123.3M
YoY Change 14.77% 5.19%
Other Long-Term Liabilities $4.139M $5.664M
YoY Change -26.92% -54.97%
Total Long-Term Liabilities $145.6M $128.9M
YoY Change 12.94% -0.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.120M $32.34M
Total Long-Term Liabilities $145.6M $128.9M
Total Liabilities $156.4M $175.7M
YoY Change -10.94% -4.12%
SHAREHOLDERS EQUITY
Retained Earnings -$383.9M -$392.1M
YoY Change -2.09% 5.68%
Common Stock $542.7M $497.8M
YoY Change 9.02% 14.53%
Preferred Stock
YoY Change
Treasury Stock (at cost) $50.00M
YoY Change 0.0%
Treasury Stock Shares 5.407M shares
Shareholders Equity $136.5M $32.07M
YoY Change
Total Liabilities & Shareholders Equity $292.9M $207.7M
YoY Change 41.02% 19.64%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$13.45M -$865.0K
YoY Change 1454.34% -93.36%
Depreciation, Depletion And Amortization $220.0K $460.0K
YoY Change -52.17% 24.32%
Cash From Operating Activities -$23.41M -$11.64M
YoY Change 101.21% -45.13%
INVESTING ACTIVITIES
Capital Expenditures $26.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $11.22M $13.23M
YoY Change -15.19% -38.24%
Cash From Investing Activities $11.19M $13.23M
YoY Change -15.39% -38.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $149.0K $62.21M
YoY Change -99.76% 67519.57%
NET CHANGE
Cash From Operating Activities -$23.41M -$11.64M
Cash From Investing Activities $11.19M $13.23M
Cash From Financing Activities $149.0K $62.21M
Net Change In Cash -$12.55M $63.73M
YoY Change -119.69% 20795.74%
FREE CASH FLOW
Cash From Operating Activities -$23.41M -$11.64M
Capital Expenditures $26.00K $0.00
Free Cash Flow -$23.44M -$11.64M
YoY Change 101.44% -45.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei No Trading Symbol Flag
NoTradingSymbolFlag
true
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001012477
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
avdl:AccountingStandardsUpdate202006Member
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
AVADEL PHARMACEUTICALS PLC
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L2
CY2021Q1 dei Entity File Number
EntityFileNumber
000-28508
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1341933
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
10 Earlsfort Terrace
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Dublin 2
CY2021Q1 dei Entity Address Country
EntityAddressCountry
IE
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
D02 T380
CY2021Q1 dei City Area Code
CityAreaCode
1
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
485-1200
CY2021Q1 dei Security12b Title
Security12bTitle
Ordinary Shares, nominal value $0.01 per share**
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58487551 shares
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12243000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2457000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3852000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5530000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11012000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7913000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
203000 USD
CY2021Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0 USD
CY2020Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2478000 USD
CY2021Q1 us-gaap Restructuring Charges
RestructuringCharges
-53000 USD
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
159000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
14811000 USD
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
18740000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14811000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6497000 USD
CY2021Q1 us-gaap Investment Income Net
InvestmentIncomeNet
610000 USD
CY2020Q1 us-gaap Investment Income Net
InvestmentIncomeNet
-378000 USD
CY2021Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
1929000 USD
CY2020Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
3190000 USD
CY2021Q1 avdl Gain Loss On Release Of Certain Liabilities
GainLossOnReleaseOfCertainLiabilities
78000 USD
CY2020Q1 avdl Gain Loss On Release Of Certain Liabilities
GainLossOnReleaseOfCertainLiabilities
0 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-310000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16052000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10375000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2607000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9510000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13445000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-865000 USD
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58443000 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41057000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58443000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41057000 shares
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13445000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-865000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-718000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-177000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-55000 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-49000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-537000 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-644000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1255000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-821000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14700000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1686000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59172000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71722000 USD
CY2021Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
145803000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
149680000 USD
CY2021Q1 avdl Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
3108000 USD
CY2020Q4 avdl Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
3326000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
34231000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
38726000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
242314000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
263454000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
344000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
359000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2427000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2604000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
16836000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
16836000 USD
CY2021Q1 avdl Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
3303000 USD
CY2020Q4 avdl Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
3445000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27717000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24939000 USD
CY2021Q1 us-gaap Assets
Assets
292941000 USD
CY2020Q4 us-gaap Assets
Assets
311637000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
484000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
474000 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2824000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2934000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4297000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6501000 USD
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1515000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5200000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9120000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15109000 USD
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
141461000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
128210000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1717000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1840000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4139000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4212000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
156437000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
149371000 USD
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
488000 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
488000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
488000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
488000 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
5000 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
5000 USD
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58488000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58488000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58396000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58396000 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
584000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
583000 USD
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
542093000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
566916000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-383872000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-384187000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-22306000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21051000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
136504000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
162266000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
292941000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
311637000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
162266000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13445000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1255000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
106000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 USD
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
43000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1728000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
136504000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-29199000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-865000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-821000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1389000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
60733000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
88000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
742000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
32067000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13445000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-865000 USD
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
218000 USD
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
456000 USD
CY2021Q1 avdl Acquisition Related Contingent Consideration Remeasurement
AcquisitionRelatedContingentConsiderationRemeasurement
0 USD
CY2020Q1 avdl Acquisition Related Contingent Consideration Remeasurement
AcquisitionRelatedContingentConsiderationRemeasurement
2478000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23413000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11636000 USD
CY2021Q1 avdl Financing Related Contingent Consideration Remeasurement
FinancingRelatedContingentConsiderationRemeasurement
0 USD
CY2020Q1 avdl Financing Related Contingent Consideration Remeasurement
FinancingRelatedContingentConsiderationRemeasurement
310000 USD
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
312000 USD
CY2020Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1573000 USD
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2534000 USD
CY2020Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-8440000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1728000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
742000 USD
CY2021Q1 avdl Gain Loss On Release Of Certain Liabilities
GainLossOnReleaseOfCertainLiabilities
78000 USD
CY2020Q1 avdl Gain Loss On Release Of Certain Liabilities
GainLossOnReleaseOfCertainLiabilities
0 USD
CY2021Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
561000 USD
CY2020Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
573000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
517000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-47000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3736000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-899000 USD
CY2021Q1 avdl Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
-80000 USD
CY2020Q1 avdl Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
-160000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3789000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1187000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2112000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4905000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
0 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
2253000 USD
CY2021Q1 avdl Earn Out Payment In Excess Of Acquisition Date Fair Value
EarnOutPaymentInExcessOfAcquisitionDateFairValue
0 USD
CY2020Q1 avdl Earn Out Payment In Excess Of Acquisition Date Fair Value
EarnOutPaymentInExcessOfAcquisitionDateFairValue
1774000 USD
CY2021Q1 us-gaap Payments For Royalties
PaymentsForRoyalties
0 USD
CY2020Q1 us-gaap Payments For Royalties
PaymentsForRoyalties
291000 USD
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
618000 USD
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
3148000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
149000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
26000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2021Q1 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
8250000 USD
CY2020Q1 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 USD
CY2021Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
40736000 USD
CY2020Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
14788000 USD
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
37769000 USD
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1562000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11191000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13226000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
60733000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1477000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
149000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62210000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-477000 USD
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
3234000 USD
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-68000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12550000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
63732000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71722000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9774000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59172000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73506000 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
3234000 USD
CY2021Q1 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
0 USD
CY2020Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
0 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
144708000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1448000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
353000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
145803000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
147903000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1815000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
38000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
149680000 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
11000 USD
CY2020Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
276000 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
68000 USD
CY2020Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
872000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
16836000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
16836000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
203000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
CY2020Q4 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
0 USD
CY2021Q1 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
0 USD
CY2019Q4 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
17327000 USD
CY2020Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
2065000 USD
CY2020Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
2788000 USD
CY2020Q1 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
18050000 USD
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
141461000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
128210000 USD
CY2018Q1 avdl American Depository Shares Conversion Ratio
AmericanDepositorySharesConversionRatio
92.6956 Rate
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2607000 USD
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.162
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9510000 USD
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.917
CY2021Q1 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
258000 USD
CY2020Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
341000 USD
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4990000 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1018000 USD
CY2021Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1477000 USD
CY2020Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1477000 USD
CY2021Q1 avdl Guarantee Current
GuaranteeCurrent
272000 USD
CY2020Q4 avdl Guarantee Current
GuaranteeCurrent
318000 USD
CY2021Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
18835000 USD
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
18615000 USD
CY2021Q1 avdl Short Term Note Receivable
ShortTermNoteReceivable
8250000 USD
CY2020Q4 avdl Short Term Note Receivable
ShortTermNoteReceivable
16500000 USD
CY2021Q1 us-gaap Other Assets Current
OtherAssetsCurrent
149000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
457000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
34231000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
38726000 USD
CY2021Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
20790000 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
18256000 USD
CY2021Q1 avdl Guarantee Noncurrent
GuaranteeNoncurrent
980000 USD
CY2020Q4 avdl Guarantee Noncurrent
GuaranteeNoncurrent
1050000 USD
CY2021Q1 avdl Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent
OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent
5550000 USD
CY2020Q4 avdl Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent
OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent
5201000 USD
CY2021Q1 avdl Other Noncurrent Receivables
OtherNoncurrentReceivables
397000 USD
CY2020Q4 avdl Other Noncurrent Receivables
OtherNoncurrentReceivables
432000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27717000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24939000 USD
CY2021Q1 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
738000 USD
CY2020Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1697000 USD
CY2021Q1 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
287000 USD
CY2020Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
520000 USD
CY2021Q1 avdl Accrued Trade Discounts And Rebates
AccruedTradeDiscountsAndRebates
912000 USD
CY2020Q4 avdl Accrued Trade Discounts And Rebates
AccruedTradeDiscountsAndRebates
1030000 USD
CY2021Q1 avdl Accrued Contract Research Organization Charges
AccruedContractResearchOrganizationCharges
690000 USD
CY2020Q4 avdl Accrued Contract Research Organization Charges
AccruedContractResearchOrganizationCharges
473000 USD
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1670000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2781000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4297000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6501000 USD
CY2021Q1 avdl Accrued Interest Current
AccruedInterestCurrent
1078000 USD
CY2020Q4 avdl Accrued Interest Current
AccruedInterestCurrent
2695000 USD
CY2021Q1 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
0 USD
CY2020Q4 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
2026000 USD
CY2021Q1 avdl Other Guarantor Obligations Current Carrying Value
OtherGuarantorObligationsCurrentCarryingValue
272000 USD
CY2020Q4 avdl Other Guarantor Obligations Current Carrying Value
OtherGuarantorObligationsCurrentCarryingValue
319000 USD
CY2021Q1 avdl Other Liabilities Miscellaneous Current
OtherLiabilitiesMiscellaneousCurrent
165000 USD
CY2020Q4 avdl Other Liabilities Miscellaneous Current
OtherLiabilitiesMiscellaneousCurrent
160000 USD
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1515000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5200000 USD
CY2021Q1 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
3143000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
3143000 USD
CY2021Q1 us-gaap Guaranty Liabilities
GuarantyLiabilities
983000 USD
CY2020Q4 us-gaap Guaranty Liabilities
GuarantyLiabilities
1053000 USD
CY2021Q1 us-gaap Other Long Term Debt
OtherLongTermDebt
13000 USD
CY2020Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
16000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4139000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4212000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13445000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-865000 USD
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58443000 shares
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-55000 USD
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41057000 shares
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2020Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58443000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41057000 shares
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15275 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15858 shares
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-49000 USD
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12243000 USD
CY2021Q1 avdl Percentage Of Royalty Payable On Net Sales
PercentageOfRoyaltyPayableOnNetSales
0.15
CY2021Q1 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
1255000 USD
CY2021Q1 avdl Guarantee Asset Current Carrying Value
GuaranteeAssetCurrentCarryingValue
1252000 USD

Files In Submission

Name View Source Status
0001012477-21-000008-index-headers.html Edgar Link pending
0001012477-21-000008-index.html Edgar Link pending
0001012477-21-000008.txt Edgar Link pending
0001012477-21-000008-xbrl.zip Edgar Link pending
avdl-20210331.htm Edgar Link pending
avdl-20210331.xsd Edgar Link pending
avdl-20210331_cal.xml Edgar Link unprocessable
avdl-20210331_def.xml Edgar Link unprocessable
avdl-20210331_htm.xml Edgar Link completed
avdl-20210331_lab.xml Edgar Link unprocessable
avdl-20210331_pre.xml Edgar Link unprocessable
exhibit101q12021.htm Edgar Link pending
exhibit101q12021001.jpg Edgar Link pending
exhibit101q12021002.jpg Edgar Link pending
exhibit101q12021003.jpg Edgar Link pending
exhibit101q12021004.jpg Edgar Link pending
exhibit101q12021005.jpg Edgar Link pending
exhibit101q12021006.jpg Edgar Link pending
exhibit101q12021007.jpg Edgar Link pending
exhibit101q12021008.jpg Edgar Link pending
exhibit101q12021009.jpg Edgar Link pending
exhibit101q12021010.jpg Edgar Link pending
exhibit101q12021011.jpg Edgar Link pending
exhibit101q12021012.jpg Edgar Link pending
exhibit101q12021013.jpg Edgar Link pending
exhibit101q12021014.jpg Edgar Link pending
exhibit101q12021015.jpg Edgar Link pending
exhibit101q12021016.jpg Edgar Link pending
exhibit101q12021017.jpg Edgar Link pending
exhibit311q12021.htm Edgar Link pending
exhibit312q12021.htm Edgar Link pending
exhibit321q12021.htm Edgar Link pending
exhibit322q12021.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending